Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cytokinetics, Inc.

http://www.cytokinetics.com

Latest From Cytokinetics, Inc.

EU Crunch Time For Myriad Drugs Marks A Busy May Meeting For CHMP

The latest meeting of the European Medicines Agency’s human medicines committee, the CHMP, is taking place this week. Decisions are expected for 13 drug marketing applications, there will be a number of oral explanation meetings, and activity is expected relating to a drug at the center of a case involving the European Commission’s rejection of an EMA recommendation.

Drug Review Approvals

Finance Watch: Cytokinetics Accesses Up To $1bn-Plus, Confirms No-Sale Plan

Public Company Edition: Cytokinetics executed a royalty financing deal for up to $575m and grossed $500m in a follow-on offering. Also, GSK grossed £1.25bn ($1.58bn) in sale of final Haleon shares, Bicycle raised $555m in a private placement and Apellis accessed up to $475m in debt.

Financing Growth

Chinese Radiopharma Developers Continue Fundraising Spree

Reflecting global interest in the field, Chinese radiopharma specialists PharmadaX Genesis, LNC Biotechnology and SmartNuclide have been on a winning streak to secure venture capital funding. Separately, Impact and Arnatar raised around $50m each in their latest venture capital- and private equity-backed fundraisings.

China Financing

Cytokinetics’ Aficamten Data Could Be Best In Class, Cardiologists Say

The company released detailed data from the Phase III SEQUOIA-HCM trial testing the cardiac myosin inhibitor in patients with obstructive hypertrophic cardiomyopathy at Heart Failure 2024.

Cardiovascular Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register